Back to top
more

Veracyte (VCYT)

(Delayed Data from NSDQ)

$31.83 USD

31.83
745,391

-0.45 (-1.39%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $31.83 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (93 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

LH Beats on Q3 Earnings, Raises Revenue Guidance Midpoint, Stock Gains

by Zacks Equity Research

Labcorp beats on earnings and revenues in the third quarter, entering the fourth half of 2024 with robust momentum.

Zacks Equity Research

DGX Stock Rises on Q3 Earnings and Revenue Beat, 2024 Sales View Up

by Zacks Equity Research

Quest Diagnostics' third-quarter 2024 performance reflects impressive DIS business growth and the benefits of new acquisitions.

Zacks Equity Research

WBA Stock Up on Q4 Earnings & Revenues Beat, Unveils Strategic Action

by Zacks Equity Research

Walgreens reports better-than-expected earnings and revenues in the fourth quarter of fiscal 2024.

Zacks Equity Research

How to Find Strong Buy Medical Stocks Using the Zacks Rank

by Zacks Equity Research

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.

Zacks Equity Research

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening

by Zacks Equity Research

Per the findings of the pivotal BLUE-C study, the Cologuard Plus test of Exact Sciences stands out for its high sensitivity at a specificity of 94%.

Zacks Equity Research

Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Urmimala Biswas headshot

3 MedTech Stocks to Buy as Monetary Policy Eases

by Urmimala Biswas

Here, we pick three MedTech stocks, VCYT, BSX and PAHC, which are anticipated to gain strongly in 2024 from the loosening of monetary policy.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Looking for Medical Stocks? The Zacks Rank Can Help You Find Winners

by Zacks Equity Research

The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Zacks Equity Research

Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Zacks Equity Research

Zacks Industry Outlook Intuitive Surgical, Masimo and Veracyte

by Zacks Equity Research

Intuitive Surgical, Masimo and Veracyte have been highlighted in this Industry Outlook article

Urmimala Biswas headshot

3 Medical Instruments Industry Stocks to Buy on genAI and M&A Boost

by Urmimala Biswas

ISRG, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar the prospects.

Zacks Equity Research

Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now

by Zacks Equity Research

Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.

Zacks Equity Research

Veracyte (VCYT) Up 9.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

The Zacks Rank Explained: How to Find Strong Buy Medical Stocks

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.

Zacks Equity Research

Should You Continue to Retain ABT Stock in Your Portfolio Now?

by Zacks Equity Research

Abbott's robust strength in Core Diagnostics and EPD businesses should continue to benefit in the upcoming quarters.

Zacks Equity Research

Here's Why Veracyte (VCYT) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Should You Consider Retaining ZBH Stock in Your Portfolio Now?

by Zacks Equity Research

Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.

Zacks Equity Research

Should You Continue to Retain PODD Stock in Your Portfolio Now?

by Zacks Equity Research

Insulet's Omnipod 5 is set to drive growth in the upcoming quarters. Meanwhile, the stock is facing challenges due to economic uncertainties.

Zacks Equity Research

Should You Consider Retaining Bruker Stock in Your Portfolio Now?

by Zacks Equity Research

BRKR's robust growth potential across its major segments is encouraging. Yet, macro woes and competitive pressure can pose challenges.

Nilanjan Choudhury headshot

5 Relative Price Strength Stocks That You Should Buy Now

by Nilanjan Choudhury

SNCR, MCY, UHS, VCYT and MWA are five stocks with explosive relative price strength.

Zacks Equity Research

Is It Apt to Hold Globus Medical Stock in Your Portfolio Now?

by Zacks Equity Research

GMED's robust prospects in the musculoskeletal field and the synergies from the NuVasive merger bode well. Yet, macroeconomic issues can affect performance.

Zacks Equity Research

Should You Hold Labcorp (LH) Stock in Your Portfolio Now?

by Zacks Equity Research

Labcorp's (LH) slew of partnerships and acquisitions and robust efforts in high-growth areas bode well.

Zacks Equity Research

Alcon (ALC) Q2 Earnings Meet Estimates, Revenues Increase Y/Y

by Zacks Equity Research

Alcon (ALC) delivers impressive growth in Implantables and Contact Lenses in the second quarter of 2024.

Zacks Equity Research

Veracyte (VCYT) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?